Treatment challenges and delivery systems in immunomodulation and probiotic therapies for periodontitis

References

• Joshi D, Garg T, Goyal AK, et al. Advanced drug delivery approaches against periodontitis. Drug Deliv. 2016;23(2):363–377.
   PubMed Web of Science ®Google Scholar
• Zupancic S, Kocbek P, Baumgartner S, et al. Contribution of Nanotechnology to improved treatment of periodontal disease. Curr Pharm Des. 2015;21(22):3257–3271.
   PubMed Web of Science ®Google Scholar
• Mombelli A. Microbial colonization of the periodontal pocket and its significance for periodontal therapy.Periodontol. 2000 [2018 Feb];76(1):85–96.
   Google Scholar
• Listl S, Galloway J, Mossey PA, et al. Global economic impact of dental diseases. J Dent Res. 2015 Oct;94(10):1355–1361.
   PubMed Web of Science ®Google Scholar
• Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. Journal of Periodontology. 2018;89:S173–S182.
   PubMed Web of Science ®Google Scholar
• Hajishengallis G. Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends Immunol. 2014;35(1):3–11.
   PubMed Web of Science ®Google Scholar
• Kamma J. EFP publishes first evidence-based treatment guidelines for periodontitis. Perio insight. 2020.13:1–8.
   Google Scholar
• Sanz M, Herrera D, Kebschull M, et al. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47(Suppl 22):4–60.
   PubMedGoogle Scholar
• Kornman KS, Giannobile WV, Duff GW. Quo vadis: what is the future of periodontics? How will we get there?Periodontol. 2000 [2017 Oct];75(1):353–371.
   Google Scholar
• Makkawi H, Hoch S, Burns E, et al. Porphyromonas gingivalis Stimulates TLR2-PI3K signaling to escape immune clearance and induce bone resorption independently of MyD88. Front Cell Infect Microbiol. 2017;7:359.
   PubMed Web of Science ®Google Scholar
• Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015 Jan;15(1):30–44.
   PubMed Web of Science ®Google Scholar
• Hajishengallis G, Chavakis T, Lambris JD. Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy.Periodontol. 2000 [2020 Oct];84(1):14–34.
   Google Scholar
• Pan W, Wang Q, Chen Q. The cytokine network involved in the host immune response to periodontitis. Int J Oral Sci. 2019 Nov 5;11(3):30.
   PubMed Web of Science ®Google Scholar
• Yousefi L, Leylabadlo HE, Pourlak T, et al. Oral spirochetes: pathogenic mechanisms in periodontal disease. Microb Pathog. 2020 Jul;144:104193.
   PubMed Web of Science ®Google Scholar
• AlQranei MS, Chellaiah MA. Osteoclastogenesis in periodontal diseases: possible mediators and mechanisms. J Oral Biosci. 2020 Jun;62(2):123–130.
   PubMed Web of Science ®Google Scholar
• Sima C, Van Dyke TE. Systems medicine and periodontal diseases. Translational Systems Medicine and Oral Disease. 2020;249–282.
   Google Scholar
• Cheng Z, Meade J, Mankia K, et al. Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):19–30.
   PubMed Web of Science ®Google Scholar
• Steinberg D, Friedman M. Sustained-release delivery of antimicrobial drugs for the treatment of periodontal diseases: fantasy or already reality?Periodontol. 2000 [2020 Oct];84(1):176–187.
   Google Scholar
• Annaji S, Sarkar I, Rajan P, et al. Efficacy of photodynamic therapy and lasers as an adjunct to scaling and root planing in the treatment of aggressive periodontitis - A clinical and microbiologic short term study. J Clin Diagn Res. 2016;10(2):ZC08–ZC12.
   PubMed Web of Science ®Google Scholar
• Maekawa T, Hajishengallis G. Topical treatment with probiotic Lactobacillus brevis CD2 inhibits experimental periodontal inflammation and bone loss. J Periodontal Res. 2014 Dec;49(6):785–791.
   PubMed Web of Science ®Google Scholar
• Rajeshwari RR, Dhamecha D, Jagwani S, et al. Local drug delivery systems in the management of periodontitis: a scientific review. J Control Release. 2019 Aug;10(307):393–409.
   Google Scholar
• Geskovski N, Sazdovska SD, Gjosheva S, et al. Rational development of nanomedicines for molecular targeting in periodontal disease. Arch Oral Biol. 2018 Sep;93:31–46.
   PubMed Web of Science ®Google Scholar
• Cafferata EA, Alvarez C, Diaz KT, et al. Multifunctional nanocarriers for the treatment of periodontitis: immunomodulatory, antimicrobial, and regenerative strategies. Oral Dis. 2019 Nov;25(8):1866–1878.
   PubMed Web of Science ®Google Scholar
• Warrier A, Mazumder N, Prabhu S, et al. Photodynamic therapy to control microbial biofilms. Photodiagnosis Photodyn Ther. 2020;3:102090.
   Google Scholar
• Akram Z, Shafqat SS, Aati S, et al. Clinical efficacy of probiotics in the treatment of gingivitis: a systematic review and meta-analysis. Aust Dent J. 2020 Mar;65(1):12–20.
   PubMed Web of Science ®Google Scholar
• Myneni SR, Brocavich K, Hw H. Biological strategies for the prevention of periodontal disease: probiotics and vaccines.Periodontol. 2000 [2020 Oct];84(1):161–175.
   Google Scholar
• Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007 Dec;57(8):552–556.
   PubMed Web of Science ®Google Scholar
• O’Brien-Simpson NM, Holden JA, Lenzo JC, et al. A therapeutic Porphyromonas gingivalis gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis. NPJ Vaccines. 2016;1(1):16022.
   PubMedGoogle Scholar
• Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016 Apr 22;352(6284):aaf1098.
   PubMed Web of Science ®Google Scholar
• Persson GR, Engel D, Whitney C, et al. Immunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates. Infect Immun. 1994;62(3):1026–1031.
   PubMed Web of Science ®Google Scholar
• Herminajeng E, Asmara W, Yuswanto A, et al. Protective humoral immunity induced by surface-associated material from Actinobacillus actinomycetemcomitans in mice. Microbes Infect. 2001 Oct;3(12):997–1003.
   PubMed Web of Science ®Google Scholar
• Rajapakse PS, O’Brien-Simpson NM, Slakeski N, et al. Immunization with the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model. Infect Immun. 2002 May;70(5):2480–2486.
   PubMed Web of Science ®Google Scholar
• Evans RT, Klausen B, Sojar HT, et al. Immunization with Porphyromonas (Bacteroides) gingivalis fimbriae protects against periodontal destruction. Infect Immun. 1992;60(7):2926–2935.
   PubMed Web of Science ®Google Scholar
• Puth S, Hong SH, Na HS, et al. A built-in adjuvant-engineered mucosal vaccine against dysbiotic periodontal diseases. Mucosal Immunol. 2019 Mar;12(2):565–579.
   PubMed Web of Science ®Google Scholar
• Wang L, Guan N, Jin Y, et al. Subcutaneous vaccination with Porphyromonas gingivalis ameliorates periodontitis by modulating Th17/Treg imbalance in a murine model. Int Immunopharmacol. 2015 [2015 03 01];25(1):65–73.
   PubMed Web of Science ®Google Scholar
• DeCarlo AA, Huang Y, Collyer CA, et al. Feasibility of an HA2 domain-based periodontitis vaccine. Infect Immun. 2003 Jan;71(1):562–566.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Plotkin’s Vaccines. Philadelphia (PA): Elsevier; 2018. 8, Passive Immunization; p. 84–95.
   Google Scholar
• Katoh M, Saito S, Takiguchi H, et al. Bactericidal activity of a monoclonal antibody against a recombinant 40-kDa outer membrane protein of Porphyromonas gingivalis. J Periodontol. 2000 Mar;71(3):368–375.
   PubMed Web of Science ®Google Scholar
• Okuda K, Kato T, Naito Y, et al. Protective efficacy of active and passive immunizations against experimental infection with Bacteroides gingivalis in ligated hamsters. J Dent Res. 1988 May;67(5):807–811.
   PubMed Web of Science ®Google Scholar
• Booth V, Ashley FP, Lehner T. Passive immunization with monoclonal antibodies against Porphyromonas gingivalis in patients with periodontitis. Infect Immun. 1996;64(2):422–427.
   PubMed Web of Science ®Google Scholar
• Švajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. 2012 Jun;31(3):202–222.
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015 Apr;45(4):423–440.
   PubMed Web of Science ®Google Scholar
• Maekawa T, Briones RA, Resuello RR, et al. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol. 2016 Mar;43(3):238–249.
   PubMed Web of Science ®Google Scholar
• Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763–776.
   PubMed Web of Science ®Google Scholar
• Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation.Periodontol. 2000 [2015 Oct];69(1):142–159.
   Google Scholar
• Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
   PubMed Web of Science ®Google Scholar
• Kajikawa T, Briones RA, Resuello RRG, et al. Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates. Mol Ther Methods Clin Dev. 2017 Sep 15;6:207–215.
   PubMed Web of Science ®Google Scholar
• Kourtzelis I, Mitroulis I, Von Renesse J, et al. From leukocyte recruitment to resolution of inflammation: the cardinal role of integrins. J Leukoc Biol. 2017 Sep;102(3):677–683.
   PubMed Web of Science ®Google Scholar
• Van Dyke TE. Pro-resolving mediators in the regulation of periodontal disease. Mol Aspects Med. 2017 Dec;58:21–36.
   PubMed Web of Science ®Google Scholar
• Bartold PM, Van Dyke TE. Host modulation: controlling the inflammation to control the infection.Periodontol. 2000 [2017 Oct];75(1):317–329.
   Google Scholar
• Silva N, Abusleme L, Bravo D, et al. Host response mechanisms in periodontal diseases. J Appl Oral Sci. 2015 May-Jun;23(3):329–355.
   PubMed Web of Science ®Google Scholar
• Lee CT, Teles R, Kantarci A, et al. Resolvin E1 reverses experimental periodontitis and dysbiosis. J Immunol. 2016 Oct 1;197(7):2796–2806.
   PubMed Web of Science ®Google Scholar
• Van Dyke TE, Hasturk H, Kantarci A, et al. Proresolving nanomedicines activate bone regeneration in periodontitis. J Dent Res. 2015 Jan;94(1):148–156.
   PubMed Web of Science ®Google Scholar
• Chee B, Park B, Fitzsimmons T, et al. Omega-3 fatty acids as an adjunct for periodontal therapy-a review. Clin Oral Investig. 2016 Jun;20(5):879–894.
   PubMed Web of Science ®Google Scholar
• Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015 Feb;15(2):104–116.
   PubMed Web of Science ®Google Scholar
• Chawla A. Control of macrophage activation and function by PPARs. Circ Res. 2010 May 28;106(10):1559–1569.
   PubMed Web of Science ®Google Scholar
• Yoo T, Ham SA, Hwang JS, et al. Peroxisome proliferator-activated receptor δ inhibits Porphyromonas gingivalis lipopolysaccharide-induced activation of matrix metalloproteinase-2 by downregulating NADPH oxidase 4 in human gingival fibroblasts. Mol Oral Microbiol. 2016 Oct;31(5):398–409.
   PubMed Web of Science ®Google Scholar
• Caton J, Ryan ME. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res. 2011 Feb;63(2):114–120.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Liu Y, et al. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009 Nov 24;2(98):ra75.
   PubMed Web of Science ®Google Scholar
• Abe T, AlSarhan M, Benakanakere MR, et al. The B cell-stimulatory Cytokines BLyS and APRIL are elevated in human periodontitis and are required for B cell-dependent bone loss in experimental murine periodontitis. J Immunol. 2015 Aug 15;195(4):1427–1435.
   PubMed Web of Science ®Google Scholar
• Dutzan N, Kajikawa T, Abusleme L, et al. A dysbiotic microbiome triggers TH 17 cells to mediate oral mucosal immunopathology in mice and humans. Sci Transl Med. 2018 [Oct 17];10(463):463.
   Web of Science ®Google Scholar
• Withers DR, Hepworth MR, Wang X, et al. Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med. 2016 Mar;22(3):319–323.
   PubMed Web of Science ®Google Scholar
• Belibasakis GN, Hajishengallis G. Advances in oral mucosal immunity and the microbiome. Adv Exp Med Biol. 2019;1197:1–9.
   PubMed Web of Science ®Google Scholar
• Glowacki AJ, Yoshizawa S, Jhunjhunwala S, et al. Prevention of inflammation-mediated bone loss in murine and canine periodontal disease via recruitment of regulatory lymphocytes. Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18525–18530.
   PubMed Web of Science ®Google Scholar
• Rogler G, Biedermann L, Scharl M, et al. Strategies beyond anti-tumour necrosis factor-alpha therapy: pathophysiology and clinical implications. Dig Dis. 2017;35(1–2):5–12.
   PubMed Web of Science ®Google Scholar
• Moutsopoulos NM, Zerbe CS, Wild T, et al. Interleukin-12 and Interleukin-23 Blockade in Leukocyte adhesion deficiency type 1. N Engl J Med. 2017 Mar 23;376(12):1141–1146.
   PubMed Web of Science ®Google Scholar
• Palomo L, Liu J, Bissada NF. Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy. Expert Opin Pharmacother. 2007 Feb;8(3):309–315.
   PubMed Web of Science ®Google Scholar
• Egloff-Juras C, Gallois A, Salleron J, et al. Denosumab-related osteonecrosis of the jaw: a retrospective study. J Oral Pathol Med. 2018 Jan;47(1):66–70.
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Singh N, Saluja M. Gene therapy in periodontics. J Indian Soc Periodontol. 2013;17(2):156–161.
   PubMedGoogle Scholar
• Chen W, Gao B, Hao L, et al. The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation. J Periodontal Res. 2016 Oct;51(5):647–660.
   PubMed Web of Science ®Google Scholar
• Anusaksathien O, Webb SA, Jin QM, et al. Platelet-derived growth factor gene delivery stimulates ex vivo gingival repair. Tissue Eng. 2003 Aug;9(4):745–756.
   PubMedGoogle Scholar
• Franceschi RT, Wang D, Krebsbach PH, et al. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem. 2000 Jun 6;78(3):476–486.
   PubMed Web of Science ®Google Scholar
• Hernandez-Monjaraz B, Santiago-Osorio E, Monroy-Garcia A, et al. Mesenchymal stem cells of dental origin for inducing tissue regeneration in periodontitis: a mini-review. Int J Mol Sci. 2018 [Mar 22];19(4):944.
   PubMed Web of Science ®Google Scholar
• Da Costa Gonçalves F, Grings M, Nunes NS, et al. Antioxidant properties of mesenchymal stem cells against oxidative stress in a murine model of colitis. Biotechnol Lett. 2017 Apr;39(4):613–622.
   PubMed Web of Science ®Google Scholar
• Matsubara VH, Bandara HM, Ishikawa KH, et al. The role of probiotic bacteria in managing periodontal disease: a systematic review. Expert Rev Anti Infect Ther. 2016 Jul;14(7):643–655.
   PubMed Web of Science ®Google Scholar
• Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. J Oral Microbiol. 2010;2:2. Nov 2.
   Google Scholar
• İnce G, Gürsoy H, İpçi ŞD, et al. Clinical and biochemical evaluation of lozenges containing lactobacillus reuteri as an adjunct to non-surgical periodontal therapy in chronic periodontitis. J Periodontol. 2015 Jun;86(6):746–754.
   PubMed Web of Science ®Google Scholar
• Szkaradkiewicz AK, Stopa J, Karpiński TM. Effect of oral administration involving a probiotic strain of Lactobacillus reuteri on pro-inflammatory cytokine response in patients with chronic periodontitis. Arch Immunol Ther Exp (Warsz). 2014 Dec;62(6):495–500.
   PubMed Web of Science ®Google Scholar
• Tekce M, Ince G, Gursoy H, et al. Clinical and microbiological effects of probiotic lozenges in the treatment of chronic periodontitis: a 1-year follow-up study. J Clin Periodontol. 2015 Apr;42(4):363–372.
   PubMed Web of Science ®Google Scholar
• Ho SN, Acharya A, Sidharthan S, et al. A systematic review and meta-analysis of clinical, immunological, and microbiological shift in periodontitis after nonsurgical periodontal therapy with adjunctive use of probiotics. J Evid Based Dent Pract. 2020 Mar;20(1):101397.
   PubMed Web of Science ®Google Scholar
• Ikram S, Hassan N, Raffat MA, et al. Systematic review and meta-analysis of double-blind, placebo-controlled, randomized clinical trials using probiotics in chronic periodontitis. J Investig Clin Dent. 2018 Aug;9(3):e12338.
   PubMed Web of Science ®Google Scholar
• Song D, Liu XR. Role of probiotics containing Lactobacillus reuteri in adjunct to scaling and root planing for management of patients with chronic periodontitis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4495–4505.
   PubMed Web of Science ®Google Scholar
• Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: systematic review and meta-analysis. J Dent. 2016 May;48:16–25.
   PubMed Web of Science ®Google Scholar
• Donos N, Calciolari E, Brusselaers N, et al. The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies. J Clin Periodontol. 2020 Jul;47(Suppl 22):199–238.
   PubMedGoogle Scholar
• Kang M-S, Lee D-S, Lee S-A, et al. Effects of probiotic bacterium Weissella cibaria CMU on periodontal health and microbiota: a randomised, double-blind, placebo-controlled trial. BMC Oral Health. 2020;20(1):1.
   Web of Science ®Google Scholar
• Pudgar P, Povšič K, Čuk K, et al. Probiotic strains of Lactobacillus brevis and Lactobacillus plantarum as adjunct to non-surgical periodontal therapy: 3-month results of a randomized controlled clinical trial. Clin Oral Investig. 2020 July;25(3):14.
   Web of Science ®Google Scholar
• Laleman I, Yilmaz E, Ozcelik O, et al. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015 Nov;42(11):1032–1041.
   PubMed Web of Science ®Google Scholar
• Morales A, Gandolfo A, Bravo J, et al. Microbiological and clinical effects of probiotics and antibiotics on nonsurgical treatment of chronic periodontitis: a randomized placebo- controlled trial with 9-month follow-up. J Appl Oral Sci. 2018;26(1):0.
   Google Scholar
• Mayanagi G, Kimura M, Nakaya S, et al. Probiotic effects of orally administered Lactobacillus salivarius WB21-containing tablets on periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 2009 Jun;36(6):506–513.
   PubMed Web of Science ®Google Scholar
• Invernici MM, Salvador SL, Silva PHF, et al. Effects of Bifidobacterium probiotic on the treatment of chronic periodontitis: a randomized clinical trial. J Clin Periodontol. 2018;45(10):1198–1210.
   PubMed Web of Science ®Google Scholar
• Shah MP, Gujjari SK, Chandrasekhar VS. Evaluation of the effect of probiotic (inersan®) alone, combination of probiotic with doxycycline and doxycycline alone on aggressive periodontitis - a clinical and microbiological study. J Clin Diagn Res. 2013 Mar;7(3):595–600.
   PubMedGoogle Scholar
• Horz HP, Meinelt A, Houben B, et al. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007 Apr;22(2):126–130.
   PubMedGoogle Scholar
• Bosch M, Nart J, Audivert S, et al., Isolation and characterization of probiotic strains for improving oral health. Arch Oral Biol. 57(5): 539–549. 2012.
   PubMed Web of Science ®Google Scholar
• Zupančič Š, Rijavec T, Lapanje A, et al. Nanofibers with incorporated autochthonous bacteria as potential probiotics for local treatment of periodontal disease. Biomacromolecules. 2018 Nov 12;19(11):4299–4306.
   PubMed Web of Science ®Google Scholar
• Camelo-Castillo A, Benitez-Paez A, Belda-Ferre P, et al. Streptococcus dentisani sp. nov., a novel member of the mitis group. Int J Syst Evol Microbiol. 2014;64(Pt 1):60–65.
   Google Scholar
• Esteban Fernández A, Ferrer MD, Zorraquín‐Peña I, et al. In vitro beneficial effects of Streptococcus dentisani as potential oral probiotic for periodontal diseases. J Periodontol. 2019;90(11):1346–1355.
   PubMed Web of Science ®Google Scholar
• Rupa P, Mine Y. Recent advances in the role of probiotics in human inflammation and gut health. J Agric Food Chem. 2012 Aug 29;60(34):8249–8256.
   PubMed Web of Science ®Google Scholar
• Cunningham M, Azcarate-Peril MA, Barnard A, et al. Shaping the future of probiotics and prebiotics. Trends Microbiol. 2021. 10.1016/j.tim.2021.01.003.
   PubMed Web of Science ®Google Scholar
• Moraes RM, Lescura CM, Milhan NVM, et al. Live and heat-killed Lactobacillus reuteri reduce alveolar bone loss on induced periodontitis in rats. Arch Oral Biol. 2020 Nov;119:104894.
   PubMed Web of Science ®Google Scholar
• Santos TA, Scorzoni L, Correia R, et al. Interaction between Lactobacillus reuteri and periodontopathogenic bacteria using in vitro and in vivo (G. mellonella) approaches. Pathog Dis. 2020;78(8). 10.1093/femspd/ftaa044.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Brody H, Lin GH, et al. Probiotics, including nisin-based probiotics, improve clinical and microbial outcomes relevant to oral and systemic diseases. Periodontol. 2000 [2020 Feb];82(1):173–185.
   Google Scholar
• Han N, Jia L, Su Y, et al. Lactobacillus reuteri extracts promoted wound healing via PI3K/AKT/β-catenin/TGFβ1 pathway. Stem Cell Res Ther. 2019;10(1):1.
   PubMed Web of Science ®Google Scholar
• Radaic A, Ye C, Parks B, et al. Modulation of pathogenic oral biofilms towards health with nisin probiotic. J Oral Microbiol. 2020;12(1):1809302.
   PubMed Web of Science ®Google Scholar
• Moman R, O’Neill CA, Ledder RG, et al. Mitigation of the toxic effects of periodontal pathogens by candidate probiotics in oral keratinocytes, and in an invertebrate model. Front. microbiol. 2020;11:999.
   Google Scholar
• Ikram S, Hassan N, Baig S, et al. Effect of local probiotic (Lactobacillus reuteri) vs systemic antibiotic therapy as an adjunct to non-surgical periodontal treatment in chronic periodontitis. J Investig Clin Dent. 2019 May;10(2):e12393.
   PubMed Web of Science ®Google Scholar
• Yanine N, Araya I, Brignardello-Petersen R, et al. Effects of probiotics in periodontal diseases: a systematic review. Clin Oral Investig. 2013 Sep;17(7):1627–1634.
   PubMed Web of Science ®Google Scholar
• Ishikawa KH, Mita D, Kawamoto D, et al. Probiotics alter biofilm formation and the transcription of Porphyromonas gingivalis virulence-associated genes. J Oral Microbiol. 2020;12(1):1805553.
   PubMedGoogle Scholar
• Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 2009 Feb;11(9):35.
   Google Scholar
• Kobayashi R, Kobayashi T, Sakai F, et al. Oral administration of Lactobacillus gasseri SBT2055 is effective in preventing Porphyromonas gingivalis-accelerated periodontal disease. Sci Rep. 2017 Apr 3;7(1):545.
   PubMed Web of Science ®Google Scholar
• Twetman S, Derawi B, Keller M, et al. Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. Acta Odontol Scand. 2009;67(1):19–24.
   PubMed Web of Science ®Google Scholar
• Jaffar N, Okinaga T, Nishihara T, et al. Enhanced phagocytosis of Aggregatibacter actinomycetemcomitans cells by macrophages activated by a probiotic Lactobacillus strain. J Dairy Sci. 2018 Jul;101(7):5789–5798.
   PubMed Web of Science ®Google Scholar
• Martin-Cabezas R, Davideau JL, Tenenbaum H, et al. Clinical efficacy of probiotics as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis: a systematic review and meta-analysis. J Clin Periodontol. 2016 Jun;43(6):520–530.
   PubMed Web of Science ®Google Scholar
• Golub LM, Lee HM. Periodontal therapeutics: current host-modulation agents and future directions. Periodontol 2000. 2020 Feb;82(1):186–204.
   PubMed Web of Science ®Google Scholar
• Hanes PJ, Purvis JP. Local anti-infective therapy: pharmacological agents. A systematic review. Ann Periodontol. 2003 Dec; 8(1):79–98.
   PubMedGoogle Scholar
• Soskolne WA. Subgingival delivery of therapeutic agents in the treatment of periodontal diseases. Crit Rev Oral Biol Med. 1997;8(2):164–174.
   PubMedGoogle Scholar
• Yap KCH, Pulikkotil SJ. Systemic doxycycline as an adjunct to scaling and root planing in diabetic patients with periodontitis: a systematic review and meta-analysis. BMC Oral Health. 2019 Sep 5;19(1):209.
   PubMed Web of Science ®Google Scholar
• Tan OL, Safii SH, Razali M. Commercial local pharmacotherapeutics and adjunctive agents for nonsurgical treatment of periodontitis: a contemporary review of clinical efficacies and challenges.Antibiotics (Basel). 2019 [Dec 30];9(1):1.
   Web of Science ®Google Scholar
• Badar SB, Zafar K, Ghafoor R, et al. Comparative evaluation of Chlorhexidine, Metronidazole and combination gels on gingivitis: a randomized clinical trial. Int J Surg Protoc. 2019;14:30–33.
   PubMed Web of Science ®Google Scholar
• Szulc M, Zakrzewska A, Zborowski J. Local drug delivery in periodontitis treatment: a review of contemporary literature. Dent Med Probl. 2018 Jul-Sep;55(3):333–342.
   PubMed Web of Science ®Google Scholar
• Scholz OA, Wolff A, Schumacher A, et al. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today. 2008 [2008 03 01];13(5):247–253.
   PubMed Web of Science ®Google Scholar
• James P, Worthington HV, Parnell C, et al. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017;3(3):CD008676–CD008676.
   PubMedGoogle Scholar
• Blinkhorn A, Bartold PM, Cullinan MP, et al. Is there a role for triclosan/copolymer toothpaste in the management of periodontal disease? Br Dent J. 2009 [2009 08 01];207(3):117–125.
   PubMed Web of Science ®Google Scholar
• Magaz VR, Llovera BF, Martí M, et al. Clinical impact and cosmetic acceptability of chlorhexidine-enriched toothpaste and mouthwash application on periodontal disease: a Randomized clinical study. J Contemp Dent Pract. 2018;19(11):1295–1300. cited.
   PubMedGoogle Scholar
• Zhang C, Yan L, Wang X, et al. Progress, challenges, and future of nanomedicine. Nano Today. 2020;35:101008. 2020 12 01.
   Web of Science ®Google Scholar
• Mirtič J, Ilaš J, Kristl J. Influence of different classes of crosslinkers on alginate polyelectrolyte nanoparticle formation, thermodynamics and characteristics. Carbohydr Polym. 2018 Feb;1(181):93–102.
   Google Scholar
• Matanović MR, Kristl J, Grabnar PA. Thermoresponsive polymers: insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. Int J Pharm. 2014 Sep 10;472(1–2):262–275.
   PubMed Web of Science ®Google Scholar
• Ganta S, Devalapally H, Shahiwala A, et al. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release. 2008 [2008 Mar 20];126(3):187–204.
   PubMed Web of Science ®Google Scholar
• Pelipenko J, Kocbek P, Kristl J. Critical attributes of nanofibers: preparation, drug loading, and tissue regeneration. Int J Pharm. 2015 Apr 30;484(1–2):57–74.
   PubMed Web of Science ®Google Scholar
• Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2012;64:18–23. 2012 Dec 01.
   Web of Science ®Google Scholar
• Mikac U, Sepe A, Gradišek A, et al. Dynamics of water and xanthan chains in hydrogels studied by NMR relaxometry and their influence on drug release. Int J Pharm. 2019 May;30(563):373–383.
   Google Scholar
• Sousa MGC, Maximiano MR, Costa RA, et al. Nanofibers as drug-delivery systems for infection control in dentistry. Expert Opin Drug Deliv. 2020 Jul;17(7):919–930.
   PubMed Web of Science ®Google Scholar
• Liechty WB, Peppas NA. Expert opinion: responsive polymer nanoparticles in cancer therapy.Eur J Pharm Biopharm. 2012 [2012 Feb 01];80(2):241–246.
   PubMed Web of Science ®Google Scholar
• Dubey P, Bhushan B, Sachdev A, et al. Silver-nanoparticle-Incorporated composite nanofibers for potential wound-dressing applications. J Appl Polym Sci. 2015;132(35):n/a-n/a.
   Web of Science ®Google Scholar
• Bertoncelj V, Pelipenko J, Kristl J, et al. Development and bioevaluation of nanofibers with blood-derived growth factors for dermal wound healing. Eur J Pharm Biopharm. 2014 [2014 Sept 01];88(1):64–74.
   PubMed Web of Science ®Google Scholar
• Watari F, Takashi N, Yokoyama A, et al. Material nanosizing effect on living organisms: non-specific, biointeractive, physical size effects. J R Soc Interface. 2009 [Jun 6];6 Suppl 3(Suppl3):S371–88.
   PubMedGoogle Scholar
• Joint Meeting Of The Chemicals Committee And The Working Party On Chemicals PAB. Guidance manual for the testing of manufactured nanomaterials: oecd’s sponsorship programme; First Revision. In: Directorate E, Paris (France): editor: OECD Environment, Health and Safety Publications; 2009:1–92.
   Google Scholar
• Savla R, Browne J, Plassat V, et al. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Dev Ind Pharm. 2017 Nov;43(11):1743–1758.
   PubMed Web of Science ®Google Scholar
• Kiptoo, P., Calcagno, A.M. and Siahaan, TJ. Drug Delivery. Physiological, biochemical, and chemical barriers to oral drug delivery. 2016. Chapter 2, Physiological, biochemical, and chemical barriers to oral drug delivery; p. 19–34
   Google Scholar
• Berginc K, Trontelj J, Basnet NS, et al. Physiological barriers to the oral delivery of curcumin. Pharmazie. 2012 Jun;67(6):518–524.
   PubMed Web of Science ®Google Scholar
• Zupančič Š, Preem L, Kristl J, et al. Impact of PCL nanofiber mat structural properties on hydrophilic drug release and antibacterial activity on periodontal pathogens. Eur J Pharm Sci. 2018 Sep;15(122):347–358.
   Google Scholar
• Ovais M, Zia N, Khalil AT, et al. Nanoantibiotics: recent developments and future prospects. frontiers in clinical drug research - anti-infectives: volume 5. Frontiers in Clinical Drug Research - Anti-Infectives 2019. p. 158–182.
   Google Scholar
• Tryfonidou MA, De Vries G, Hennink WE, et al. Old drugs, new tricks” – local controlled drug release systems for treatment of degenerative joint disease. Adv Drug Deliv Rev. 2020 [2020 Jan 01];160:170–185.
   PubMed Web of Science ®Google Scholar
• Haddadi A, Elamanchili P, Lavasanifar A, et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A. 2008 Mar 15;84(4):885–898.
   PubMedGoogle Scholar
• Lee BS, Lee CC, Wang YP, et al. Controlled-release of tetracycline and lovastatin by poly(D,L-lactide-co-glycolide acid)-chitosan nanoparticles enhances periodontal regeneration in dogs. Int J Nanomedicine. 2016;11:285–297.
   PubMed Web of Science ®Google Scholar
• Lin JH, Feng F, Yu MC, et al. Modulation of periodontitis progression using pH-responsive nanosphere encapsulating metronidazole or N-phenacylthialzolium bromide. J Periodontal Res. 2018 Feb;53(1):22–28.
   PubMed Web of Science ®Google Scholar
• Martin V, Ribeiro IAC, Alves MM, et al. Understanding intracellular trafficking and anti-inflammatory effects of minocycline chitosan-nanoparticles in human gingival fibroblasts for periodontal disease treatment. Int J Pharm. 2019 [2019 Dec 15];572:118821.
   PubMedGoogle Scholar
• Levingstone TJ, Herbaj S, Dunne NJ. Calcium Phosphate Nanoparticles for Therapeutic Applications in Bone Regeneration. Nanomaterials (Basel). 2019;9(11):1570.
   Google Scholar
• Arancibia R, Maturana C, Silva D, et al. Effects of chitosan particles in periodontal pathogens and gingival fibroblasts. J Dent Res. 2013 Aug;92(8):740–745.
   PubMed Web of Science ®Google Scholar
• Li X, Dong W, Nalin AP, et al. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells. Oncoimmunology. 2018;7(6):e1431085.
   PubMed Web of Science ®Google Scholar
• Bruschi ML, Borghi-Pangoni FB, Junqueira MV, et al. Nanostructures for novel therapy. Amsterdam (Netherlands): Elsevier;2017. Chapter 12, Nanostructured therapeutic systems with bioadhesive and thermoresponsive properties. p. 313–342.
   Google Scholar
• Sill TJ, Von Recum HA. Electrospinning: applications in drug delivery and tissue engineering.Biomaterials. 2008 [2008 May 01];29(13):1989–2006.
   PubMed Web of Science ®Google Scholar
• Yim EKF, Leong KW. Significance of synthetic nanostructures in dictating cellular response.Nanomedicine. 2005 [2005 Mar 01];1(1):10–21.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Hernández J. Surface chemistry of nanobiomaterials. Oxfrod (UK): William Andrew Publishing; 2016. Chapter 4, Nano-microporous structured surfaces prepared by the breath figures approach and their biorelated applications. p. 107–133.
   Google Scholar
• Pelipenko J, Kocbek P, Govedarica B, et al. The topography of electrospun nanofibers and its impact on the growth and mobility of keratinocytes. Eur J Pharm Biopharm. 2013 Jun;84(2):401–411.
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Eatemadi A. Drug loading and delivery using nanofibers scaffolds. Artif Cells Nanomed Biotechnol. 2017 Aug;45(5):881–888.
   PubMed Web of Science ®Google Scholar
• Xue J, Xie J, Liu W, et al. Electrospun nanofibers: new concepts, materials, and applications. Acc Chem Res. 2017 [2017 Aug 15];50(8):1976–1987.
   PubMed Web of Science ®Google Scholar
• Haidar MK, Eroglu H. Nanofibers: new insights for drug delivery and tissue engineering. Curr Top Med Chem. 2017;17(13):1564–1579.
   PubMed Web of Science ®Google Scholar
• Sousa MGC, Maximiano MR, Costa RA, et al. Nanofibers as drug-delivery systems for infection control in dentistry. Expert Opin Drug Deliv. 2020 [2020 Jul 02];17(7):919–930.
   PubMed Web of Science ®Google Scholar
• Zafar M, Najeeb S, Khurshid Z, et al. Potential of electrospun nanofibers for biomedical and dental applications. Materials (Basel). 2016 [Jan 26];9(2):2.
   Web of Science ®Google Scholar
• Riesbeck K, Forsgren A, Henriksson A, et al. Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother. 1998 Aug;42(8):1923–1930.
   PubMed Web of Science ®Google Scholar
• Blank M, George J, Fishman P, et al. Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis Rheumatism. 1998 Feb;41(2):224–232.
   PubMedGoogle Scholar
• Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003 Jun;3(6):359–371.
   PubMed Web of Science ®Google Scholar
• Zupančič Š, Casula L, Rijavec T, et al. Sustained release of antimicrobials from double-layer nanofiber mats for local treatment of periodontal disease, evaluated using a new micro flow-through apparatus. J Control Release. 2019 Dec;28(316):223–235.
   Google Scholar
• Vigani B, Rossi S, Sandri G, et al. Hyaluronic acid and chitosan-based nanosystems: a new dressing generation for wound care. Expert Opin Drug Deliv. 2019 Jul;16(7):715–740.
   PubMed Web of Science ®Google Scholar
• Day AJ, De La Motte CA. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005 Dec;26(12):637–643.
   PubMed Web of Science ®Google Scholar
• Kesik-Brodacka M. Progress in biopharmaceutical development. Biotechnol Appl Biochem. 2018;65(3):306–322.
   PubMed Web of Science ®Google Scholar
• Walsh G. Biopharmaceutical benchmarks 2018.Nat Biotechnol. 2018 [2018 Dec 01];36(12):1136–1145.
   PubMed Web of Science ®Google Scholar
• Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting?Eur J Pharm Biopharm. 2008 [2008 Jan 01];68(1):112–128.
   PubMed Web of Science ®Google Scholar
• Teskač K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm. 2010 May 5;390(1):61–69.
   PubMed Web of Science ®Google Scholar
• Munyendo WL, Lv H, Benza-Ingoula H, et al. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules. 2012;2(2):187–202.
   PubMedGoogle Scholar
• Baker MP, Reynolds HM, Lumicisi B, et al. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself. 2010;1(4):314–322.
   PubMedGoogle Scholar
• Xu F, Corbett B, Bell S, et al. High-throughput synthesis, analysis, and optimization of injectable hydrogels for protein delivery. Biomacromolecules. 2020 [2020 Jan 13];21(1):214–229.
   PubMed Web of Science ®Google Scholar
• Santalices I, Gonella A, Torres D, et al. Advances on the formulation of proteins using nanotechnologies. J Drug Delivery Sci Technol. 2017;42:155–180.
   Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014 Sep;13(9):655–672.
   PubMed Web of Science ®Google Scholar
• Homayun B, Lin X, Choi H-J. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129.
   PubMed Web of Science ®Google Scholar
• Jain AK, Bataille CJR, Milhas S, et al. Immunopolymer Lipid Nanoparticles for delivery of macromolecules to antigen-expressing cells. ACS Appl Bio Mater. 2020 [2020 Nov 20];3(12):8481–8495.
   Google Scholar
• Peres C, Matos AI, Conniot J, et al. Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomater. 2017 Jan;15(48):41–57.
   Google Scholar
• Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release. 2012 Jul 20;161(2):600–608.
   PubMed Web of Science ®Google Scholar
• Li M, Zhou H, Jiang W, et al. Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity. Nano Today. 2020;35:12.
   Google Scholar
• Zhang K, Tang X, Zhang J, et al. PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications. J Control Release. 2014 Jun;10(183):77–86.
   Google Scholar
• Capurso NA, Look M, Jeanbart L, et al. Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cells. Self Nonself. 2010 Oct;1(4):335–340.
   PubMedGoogle Scholar
• Lima AC, Cunha C, Carvalho A, et al. Interleukin-6 neutralization by antibodies immobilized at the surface of polymeric nanoparticles as a therapeutic strategy for arthritic diseases. ACS Appl Mater Interfaces. 2018 Apr 25;10(16):13839–13850.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Y, Liu D, et al. Ectopic expression of SIGIRR in the colon ameliorates colitis in mice by downregulating TLR4/NF-κB overactivation. Immunol Lett. 2017 Mar;183:52–61.
   PubMed Web of Science ®Google Scholar
• Abbaraju PL, Jambhrunkar M, Yang Y, et al. Asymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responses. Chem Commun (Camb). 2018 Feb 20;54(16):2020–2023.
   PubMed Web of Science ®Google Scholar
• Shahriar SMS, Mondal J, Hasan MN, et al. Electrospinning Nanofibers for Therapeutics Delivery. Nanomaterials (Basel). 2019 [Apr 3];9(4):532.
   PubMedGoogle Scholar
• Saffari M, Moghimi HR, Dass CR. Barriers to Liposomal gene delivery: from application site to the target. Iran J Pharm Res. 2016; Winter;15(Suppl):3–17.
   PubMedGoogle Scholar
• Yang N. Nonviral gene delivery system. Int J Pharm Investig. 2012;2(3):97–98.
   PubMedGoogle Scholar
• Broeckx G, Vandenheuvel D, Claes IJJ, et al. Drying techniques of probiotic bacteria as an important step towards the development of novel pharmabiotics. Int J Pharm. 2016 [2016 May 30];505(1):303–318.
   PubMedGoogle Scholar
• Škrlec K, Zupančič Š, Prpar Mihevc S, et al. Development of electrospun nanofibers that enable high loading and long-term viability of probiotics. Eur J Pharm Biopharm. 2019 Mar;136:108–119.
   PubMed Web of Science ®Google Scholar
• Crowe LM, Reid DS, Crowe JH. Is trehalose special for preserving dry biomaterials?Biophys J. 1996 [1996 Oct 01];71(4):2087–2093.
   PubMed Web of Science ®Google Scholar
• Crowe JH, Crowe LM, Chapman D. Preservation of membranes in anhydrobiotic organisms: the role of trehalose. Science. 1984 Feb 17;223(4637):701–703.
   PubMed Web of Science ®Google Scholar
• Vicario M, Santos A, Violant D, et al. Clinical changes in periodontal subjects with the probiotic Lactobacillus reuteri Prodentis: a preliminary randomized clinical trial. Acta Odontol Scand. 2013 May-Jul;71(3–4):813–819.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Fischer JT, Daniels R. Development of probiotic orodispersible tablets using mucoadhesive polymers for buccal mucoadhesion. Drug Dev Ind Pharm. 2020;46(11):1753–1762.
   PubMed Web of Science ®Google Scholar
• Teughels W, Newman MG, Coucke W, et al. Guiding periodontal pocket recolonization: a proof of concept. J Dent Res. 2007;86(11):1078–1082.
   PubMed Web of Science ®Google Scholar
• Nackaerts O, Jacobs R, Quirynen M, et al. Replacement therapy for periodontitis: pilot radiographic evaluation in a dog model. J Clin Periodontol. 2008;35(12):1048–1052.
   PubMed Web of Science ®Google Scholar
• Mirtič J, Rijavec T, Zupančič Š, et al. Development of probiotic-loaded microcapsules for local delivery: physical properties, cell release and growth. Eur J Pharm Sci. 2018 Aug;30(121):178–187.
   Google Scholar
• Zupančič Š, Škrlec K, Kocbek P, et al. Effects of electrospinning on the viability of ten species of Lactic Acid Bacteria in Poly(Ethylene Oxide) Nanofibers. Pharmaceutics. 2019;11(9):483.
   Web of Science ®Google Scholar